Compounds > s20098
Page last updated: 2024-08-25

s20098 and Depression

s20098 has been researched along with Depression in 70 studies

Research

Studies (70)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (8.57)29.6817
2010's56 (80.00)24.3611
2020's8 (11.43)2.80

Authors

AuthorsStudies
Chen, JJ; Geng, CA; Huang, XY; Li, TZ; Ma, YB; Yan, DX; Yang, TH; Zhang, XM1
Cui, P; Hao, L; He, X; Jia, Y; Liang, Z; Tong, B; Yang, F; Yuan, J; Zhao, L; Zhu, R1
Fan, C; Lan, T; Li, S; Li, Y; Mao, X; Wang, L; Wang, W; Wu, Y; Yu, SY; Zhang, Y; Zhu, Z1
Demirdas, A; Nazıroglu, M; Ovey, IS; Ozdamar Unal, G1
Jani, P; Pandya, N; Tandel, H; Vanza, J1
An, Q; Chen, Y; Li, C; Li, J; Luo, Y; Song, R; Tong, A; Yang, Y; Zhou, L1
El-Khatib, YA; Khattab, MM; Sallam, NA; Sayed, RH; Zaki, HF1
Boudah, A; Jasmin, L; Rebai, R1
Amin, N; Chen, F; Chen, S; Fang, M; Jin, W; Liu, J1
Carpenter, JS; Fogel, S; Hickie, IB; Louati, K; Porteous, M; Ray, L; Robillard, R1
Agarwal, NB; Azim, MS; Vohora, D1
Charoenphandhu, J; Charoenphandhu, N; Krishnamra, N; Lapmanee, S; Teerapornpuntakit, J1
Bouzinova, EV; Christiansen, SL; Højgaard, K; Wiborg, O1
Andreatini, R; Bassani, TB; Machado, MM; Martynhak, BJ; Moura, E; Souza, LC; Turnes, JM; Vital, MABF1
Atanasova, D; Atanasova, M; Kortenska, L; Lazarov, N; Tchekalarova, J1
Becker, A; Braun, H; Eisenacher, S; Englisch, S; Jung, HS; Lewien, A; Meyer-Lindenberg, A; Nowak, U; Thiem, J; Zink, M2
Ho, CS; Ho, RC; Lu, Y; McIntyre, RS; Wang, W1
Norman, TR; Olver, JS1
Aguado, J; Brandt, L; Cainzos-Achirica, M; Castellsagué, J; Cortés, J; Deltour, N; Falissard, B; Forns, J; Giner-Soriano, M; Hägg, D; Hallas, J; Hellfritzsch, M; Jacquot, E; Morros, R; Perez-Gutthann, S; Perlemuter, G; Pladevall-Vila, M; Poblador-Plou, B; Pottegård, A; Prados-Torres, A; Reinders, T; Reutfors, J; Schink, T; Timmer, A1
Morris, M; Sinnott, C1
Norman, TR1
Bruno, A; Caminiti, M; Cogliandro, N; Lorusso, S; Micò, U; Muscatello, MR; Pandolfo, G; Zoccali, RA1
Huttner, NA; Laux, G1
Olofinjana, O; Sparshatt, A; Taylor, D; Varma, S1
Ambresin, G; Gunn, J1
De Bodinat, C; Delagrange, P; Guardiola-Lemaitre, B; Millan, MJ; Mocaër, E; Munoz, C1
Baldwin, DS; Elnazer, HY1
Balakina, IV; Golovanova, EN; Mironova, TIa1
Boulle, F; Gabriel, C; Lanfumey, L; Marday, S; Massart, R; Mocaer, E; Mongeau, R; Païzanis, E; Stragier, E; Zaidan, L1
Howland, RH1
Barylnik, JB; Filippova, NV; Trayber, LV1
Avila, A; Bello, J; Caballol, N; Cardona, X; Leon, L; Martin-Baranera, M; Millet, P1
Biggio, G; De Berardis, D; De Remigis, V; Di Giannantonio, M; Di Nicola, M; Janiri, L; Lucidi Pressanti, G; Martinotti, G; Pettorruso, M; Ricci, V; Valchera, A; Varasano, PA1
Gulec, M; Kara, A; Ozcan, H; Ozkanlar, S; Polat, E; Yucel, A; Yucel, N1
Gavrilova, SI; Kalyn, YB; Kornilov, VV; Safarova, TP; Sheshenin, VS; Shipilova, ES; Yakovleva, OB1
Antonen, EG; Kruchek, MM; Nikitina, MV1
Ezzikouri, S; Hai-Ying, C; Kayesh, ME; Kitab, B; Kohara, M; Kouji, H; Nagano, K; Nakano, H; Rebbani, K; Tsukiyama-Kohara, K; Yamaguchi, C1
Khanam, R; Thomas, J; Vohora, D1
Poleszak, E; Serefko, A; Stasiuk, W; Świąder, K; Szopa, A; Wlaź, P; Wyska, E1
Demirdaş, A; Nazıroğlu, M; Ünal, GÖ1
Blum, J; Suenderhauf, C; Vogel, M; Walter, A; Zormann, A1
Carano, A; de Bartolomeis, A; De Berardis, D; De Lauretis, I; Di Giannantonio, M; Fornaro, M; Girinelli, G; Iasevoli, F; Martinotti, G; Matarazzo, I; Mazza, M; Orsolini, L; Perna, G; Serroni, N; Tomasetti, C; Valchera, A; Vellante, F1
Larsen, ER; Roopan, S1
Cardinali, DP; Hardeland, R; Pandi-Perumal, SR; Poeggeler, B; Spence, DW; Srinivasan, V; Trakht, I1
Kálmán, J; Kálmán, S1
Baylé, FJ; Hajak, G; Hoogendijk, WJ; Kasper, S; Montejo, AL; Picarel-Blanchot, F; Quera-Salva, MA; Rybakowski, JK; Smeraldi, E; Wirz-Justice, AM; Wulff, K1
Abreu-Gonzalez, P; Morera-Fumero, AL1
Zlokazova, MV1
Somoskovi, C; Sumegi, A1
Green, B1
Banasr, M; Daszuta, A; Fagioli, F; Gabriel, C; Maccari, S; Mairesse, J; McEwen, B; Mocaer, E; Morley-Fletcher, S; Nicoletti, F; Soumier, A1
Bogolepova, AN; Chukanova, AS; Chukanova, EI; Gracheva, IIu; Semushkina, EG; Smirnova, MIu1
Dubois, M; El Yacoubi, M; Gabriel, C; Mocaër, E; Vaugeois, JM1
Brown, GM; Brzezinski, A; Cardinali, DP; Srinivasan, V1
Calabrese, F; Molteni, R; Musazzi, L; Popoli, M; Racagni, G; Riva, MA; Tardito, D1
Kennedy, SH; Majadas, S; Montejo, A; Rizvi, SJ1
Baulieu, EE; Bianchi, M; Gabriel, C; Ladurelle, N; Mocaër, E; Viggiano, A1
Bellantuono, C; Catena-Dell'Osso, M; Marazziti, D; Rotella, F1
Sapetti, A1
Levin, IaI1
Medvedev, VE1
Kolesnikov, DB; Kotov, AM; Stotsky, AD1
Pizova, NV1
Boyer, PA; Gruca, P; Mocaër, E; Papp, M1
Barden, N; Labbé, M; Mocaër, E; Rochford, J; Shink, E; Vacher, R1
Cardinali, DP; Monti, MJ; Pandi-Perumal, SR; Srinivasan, V1

Reviews

15 review(s) available for s20098 and Depression

ArticleYear
Agomelatine for depression: expanding the horizons?
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:6

    Topics: Acetamides; Antidepressive Agents; Bipolar Disorder; Circadian Rhythm; Depression; Diabetes Mellitus, Type 2; Humans; Hypnotics and Sedatives; Seasonal Affective Disorder; Serotonin Antagonists

2019
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies.
    BMJ (Clinical research ed.), 2014, Mar-19, Volume: 348

    Topics: Acetamides; Antidepressive Agents; Depression; Humans; Randomized Controlled Trials as Topic; Treatment Outcome

2014
Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.
    British journal of pharmacology, 2014, Volume: 171, Issue:15

    Topics: Acetamides; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Circadian Rhythm; Depression; Humans; Neurogenesis; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists

2014
[Modern approaches to the synchronization of circadian rhythms in treatment of depression].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2014, Volume: 114, Issue:11

    Topics: Acetamides; Animals; Circadian Rhythm; Depression; Humans; Hypnotics and Sedatives; Receptors, Melatonin

2014
Use of antidepressants in patients with depression and comorbid diabetes mellitus: a systematic review.
    Acta neuropsychiatrica, 2017, Volume: 29, Issue:3

    Topics: Acetamides; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Comorbidity; Depression; Diabetes Mellitus; Double-Blind Method; Female; Humans; Hyperglycemia; Hypnotics and Sedatives; Hypoglycemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Young Adult

2017
Pathophysiology of depression: role of sleep and the melatonergic system.
    Psychiatry research, 2009, Feb-28, Volume: 165, Issue:3

    Topics: Acetamides; Antidepressive Agents; Circadian Rhythm; Depression; Humans; Melatonin; Prevalence; Receptors, Melatonin; Sleep; Sleep Stages; Sleep Wake Disorders; Suprachiasmatic Nucleus; Wakefulness

2009
[Depression as chronobiological illness].
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2009, Volume: 11, Issue:2

    Topics: Acetamides; Affect; Biological Clocks; Chronotherapy; Circadian Rhythm; Depression; Depressive Disorder, Major; Humans; Hypnotics and Sedatives; Melatonin; Mood Disorders; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Sleep; Sleep Deprivation; Sleep Wake Disorders; Suprachiasmatic Nucleus

2009
[Lights off? Neurobiological and pharmacological aspects of the melatonergic-serotonergic synergism].
    Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2010, Volume: 12, Issue:4

    Topics: Acetamides; Antidepressive Agents; Circadian Rhythm; Depression; Depressive Disorder; Drug Synergism; Humans; Hypnotics and Sedatives; Melatonin; Meta-Analysis as Topic; Receptors, Melatonin; Serotonin; Sleep Disorders, Circadian Rhythm

2010
Focus on agomelatine.
    Current medical research and opinion, 2011, Volume: 27, Issue:4

    Topics: Acetamides; Adult; Animals; Antidepressive Agents; Anxiety; Bipolar Disorder; Depression; Dose-Response Relationship, Drug; Humans; Hypnotics and Sedatives; Models, Biological; Sleep; Treatment Outcome

2011
Melatonin and its analogs in insomnia and depression.
    Journal of pineal research, 2012, Volume: 52, Issue:4

    Topics: Acetamides; Animals; Depression; Humans; Hypnotics and Sedatives; Indenes; Melatonin; Mice; Sleep Initiation and Maintenance Disorders

2012
Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2011, Volume: 12, Issue:8

    Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depression; Humans; Receptor, Serotonin, 5-HT2C; Receptors, Melatonin; Serotonin 5-HT2 Receptor Antagonists

2011
The effects of agomelatine on sexual function in depressed patients and healthy volunteers.
    Human psychopharmacology, 2011, Volume: 26, Issue:8

    Topics: Acetamides; Animals; Antidepressive Agents; Depression; Humans; Melatonin; Selective Serotonin Reuptake Inhibitors; Sexual Behavior; Sexual Dysfunctions, Psychological; Treatment Outcome

2011
Emerging targets for the pharmacological treatment of depression: focus on melatonergic system.
    Current medicinal chemistry, 2012, Volume: 19, Issue:3

    Topics: Acetamides; Antidepressive Agents; Circadian Clocks; Depression; Humans; Indenes; Melatonin; Receptors, Melatonin

2012
[Antidepressants in cardiology].
    Klinicheskaia meditsina, 2012, Volume: 90, Issue:10

    Topics: Acetamides; Amitriptyline; Antidepressive Agents; Cardiovascular Diseases; Depression; Humans; Sertraline

2012
Could agomelatine be the ideal antidepressant?
    Expert review of neurotherapeutics, 2006, Volume: 6, Issue:11

    Topics: Acetamides; Animals; Antidepressive Agents; Clinical Trials as Topic; Depression; Humans; Hypnotics and Sedatives; Practice Patterns, Physicians'; Treatment Outcome

2006

Trials

6 trial(s) available for s20098 and Depression

ArticleYear
Agomelatine might be more appropriate for elderly, depressed, type 2 diabetes mellitus patients than paroxetine/fluoxetine.
    Aging, 2021, 10-05, Volume: 13, Issue:19

    Topics: Acetamides; Adult; Aged; Aging; Antidepressive Agents, Second-Generation; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Humans; Hypnotics and Sedatives; Male; Middle Aged; Paroxetine

2021
Agomelatine in the treatment of fibromyalgia: a 12-week, open-label, uncontrolled preliminary study.
    Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:4

    Topics: Acetamides; Affect; Analgesics; Antidepressive Agents; Anxiety; Chronic Pain; Cognition; Depression; Executive Function; Female; Fibromyalgia; Humans; Middle Aged; Neuropsychological Tests; Pain Measurement; Pilot Projects; Psychiatric Status Rating Scales; Time Factors; Treatment Outcome

2013
Agomelatine Increases BDNF Serum Levels in Depressed Patients in Correlation with the Improvement of Depressive Symptoms.
    The international journal of neuropsychopharmacology, 2016, Volume: 19, Issue:5

    Topics: Acetamides; Affect; Aged; Antidepressive Agents; Biomarkers; Brain-Derived Neurotrophic Factor; Depression; Female; Humans; Italy; Linear Models; Male; Middle Aged; Remission Induction; Time Factors; Treatment Outcome; Up-Regulation

2016
Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    The Journal of clinical psychiatry, 2010, Volume: 71, Issue:2

    Topics: Acetamides; Actigraphy; Adolescent; Adult; Antidepressive Agents; Anxiety; Circadian Rhythm; Depression; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Middle Aged; Motor Activity; Psychiatric Status Rating Scales; Rest; Sertraline; Severity of Illness Index; Sleep; Treatment Outcome

2010
[The use of valdoxan in the treatment of post-stroke depression].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2011, Volume: 111, Issue:4

    Topics: Acetamides; Aged; Aged, 80 and over; Antidepressive Agents; Cognition; Depression; Drug Administration Schedule; Emotions; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Stroke

2011
[Valdoxan (agomelatine) in the treatment of depression in patients with cerebrovascular diseases: the results of the Russian multicenter naturalistic study "Resonance"].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2012, Volume: 112, Issue:12

    Topics: Acetamides; Adult; Cerebrovascular Disorders; Depression; Female; Humans; Male; Russia; Treatment Outcome

2012

Other Studies

49 other study(ies) available for s20098 and Depression

ArticleYear
Synthesis and biological evaluation of magnolol derivatives as melatonergic receptor agonists with potential use in depression.
    European journal of medicinal chemistry, 2018, Aug-05, Volume: 156

    Topics: Animals; Antidepressive Agents; Biphenyl Compounds; Brain; Depression; Female; HEK293 Cells; Hindlimb Suspension; Humans; Lignans; Male; Mice; Rats, Sprague-Dawley; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2

2018
Agomelatine rescues lipopolysaccharide-induced neural injury and depression-like behaviors via suppression of the Gαi-2-PKA-ASK1 signaling pathway.
    Journal of neuroinflammation, 2022, May-24, Volume: 19, Issue:1

    Topics: Acetamides; Animals; Antidepressive Agents; Depression; GTP-Binding Protein alpha Subunits, Gi-Go; Hippocampus; Lipopolysaccharides; MAP Kinase Kinase Kinase 5; Naphthalenes; Neurons; Rats; Receptor, Serotonin, 5-HT2C; Signal Transduction

2022
Agomelatine attenuates calcium signaling and apoptosis via the inhibition of TRPV1 channel in the hippocampal neurons of rats with chronic mild stress depression model.
    Behavioural brain research, 2022, 09-26, Volume: 434

    Topics: Acetamides; Animals; Apoptosis; Calcium; Calcium Signaling; Depression; Dimethyl Sulfoxide; Hippocampus; Naphthalenes; Neurons; Oxidative Stress; Rats; Transient Receptor Potential Channels; TRPM Cation Channels; TRPV Cation Channels

2022
Formulation of polymeric nanoparticles of antidepressant drug for intranasal delivery.
    Therapeutic delivery, 2019, Volume: 10, Issue:11

    Topics: Acetamides; Administration, Intranasal; Animals; Antidepressive Agents; Behavior Observation Techniques; Behavior, Animal; Blood-Brain Barrier; Delayed-Action Preparations; Depression; Disease Models, Animal; Drug Carriers; Drug Compounding; Goats; Humans; Nanoparticles; Nasal Mucosa; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Toxicity Tests

2019
Scaffold hopping of agomelatine leads to enhanced antidepressant effects by modulation of gut microbiota and host immune responses.
    Pharmacology, biochemistry, and behavior, 2020, Volume: 192

    Topics: Acetamides; Animals; Antidepressive Agents; Behavior, Animal; Brain; Cytokines; Depression; Depressive Disorder; Disease Models, Animal; Food Preferences; Gastrointestinal Microbiome; Immunity; Inflammasomes; Male; Mice; Mice, Inbred C57BL; Stress, Psychological; Treatment Outcome

2020
17β-Estradiol augments the neuroprotective effect of agomelatine in depressive- and anxiety-like behaviors in ovariectomized rats.
    Psychopharmacology, 2020, Volume: 237, Issue:9

    Topics: Acetamides; Animals; Anxiety; Depression; Drug Synergism; Estradiol; Female; Hypnotics and Sedatives; Neuroprotective Agents; Ovariectomy; Rats; Rats, Wistar; Swimming

2020
Agomelatine effects on fat-enriched diet induced neuroinflammation and depression-like behavior in rats.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 135

    Topics: Acetamides; Animals; Anti-Anxiety Agents; Anti-Inflammatory Agents; Antidepressive Agents; Antioxidants; Anxiety; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; Depression; Diet, High-Fat; Disease Models, Animal; Inflammation; Inflammation Mediators; Male; Oxidative Stress; Rats, Wistar

2021
Agomelatine Softens Depressive-Like Behavior through the Regulation of Autophagy and Apoptosis.
    BioMed research international, 2021, Volume: 2021

    Topics: Acetamides; Animals; Apoptosis; Autophagy; bcl-2-Associated X Protein; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Male; MAP Kinase Signaling System; Membrane Glycoproteins; Mice; Protein-Tyrosine Kinases; Stress, Psychological

2021
Increased spindle density correlates with sleep continuity improvements following an eight-week course of a melatonin agonist in people with depression: A proof-of-concept study with agomelatine.
    The European journal of neuroscience, 2021, Volume: 54, Issue:3

    Topics: Acetamides; Adolescent; Adult; Depression; Humans; Melatonin; Sleep; Young Adult

2021
Effects of agomelatine on pentylenetetrazole-induced kindling, kindling-associated oxidative stress, and behavioral despair in mice and modulation of its actions by luzindole and 1-(m-chlorophenyl) piperazine.
    Epilepsy & behavior : E&B, 2017, Volume: 72

    Topics: Acetamides; Animals; Anticonvulsants; Antioxidants; Depression; Drug Therapy, Combination; Epilepsy; Hippocampus; Hypnotics and Sedatives; Kindling, Neurologic; Male; Mice; Oxidative Stress; Pentylenetetrazole; Seizures; Treatment Outcome; Tryptamines

2017
Agomelatine, venlafaxine, and running exercise effectively prevent anxiety- and depression-like behaviors and memory impairment in restraint stressed rats.
    PloS one, 2017, Volume: 12, Issue:11

    Topics: Acetamides; Animals; Antidepressive Agents, Second-Generation; Body Weight; Corticosterone; Depression; Feeding Behavior; Immobilization; Male; Memory Disorders; Organ Size; Physical Conditioning, Animal; Rats; Rats, Wistar; Running; Stress, Physiological; Venlafaxine Hydrochloride

2017
Disturbances of diurnal phase markers, behavior, and clock genes in a rat model of depression; modulatory effects of agomelatine treatment.
    Psychopharmacology, 2018, Volume: 235, Issue:3

    Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; CLOCK Proteins; Depression; Disease Models, Animal; Male; Melatonin; Period Circadian Proteins; Rats; Rats, Wistar; Treatment Outcome

2018
Agomelatine's effect on circadian locomotor rhythm alteration and depressive-like behavior in 6-OHDA lesioned rats.
    Physiology & behavior, 2018, 05-01, Volume: 188

    Topics: Acetamides; Animals; Circadian Rhythm; Depression; Exploratory Behavior; Food Preferences; Hypnotics and Sedatives; Locomotion; Male; Oxidopamine; Rats; Rats, Wistar; Statistics, Nonparametric; Sucrose; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase

2018
Chronic agomelatine treatment prevents comorbid depression in the post-status epilepticus model of acquired epilepsy through suppression of inflammatory signaling.
    Neurobiology of disease, 2018, Volume: 115

    Topics: Acetamides; Animals; Antidepressive Agents; Comorbidity; Depression; Disease Models, Animal; Hypnotics and Sedatives; Inflammation Mediators; Male; Rats; Rats, Wistar; Signal Transduction; Status Epilepticus; Treatment Outcome

2018
Response to Agomelatine Treatment is Independent of Smoking Status and Dosage: Results From the AGOPSYCH Study.
    Pharmacopsychiatry, 2019, Volume: 52, Issue:3

    Topics: Acetamides; Adult; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Smoking; Treatment Outcome; Young Adult

2019
Neurocognitive Effects of Agomelatine Treatment in Schizophrenia Patients Suffering From Comorbid Depression: Results From the AGOPSYCH Study.
    Journal of clinical psychopharmacology, 2018, Volume: 38, Issue:4

    Topics: Acetamides; Adult; Antipsychotic Agents; Cognitive Dysfunction; Depression; Drug Therapy, Combination; Female; Humans; Male; Neuropsychological Tests; Schizophrenia

2018
Agomelatine-induced modulation of brain-derived neurotrophic factor (BDNF) in the rat hippocampus.
    Life sciences, 2018, Oct-01, Volume: 210

    Topics: Acetamides; Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depression; Disease Models, Animal; Gene Expression Regulation; Hippocampus; Hypnotics and Sedatives; Male; Rats; Rats, Sprague-Dawley; Stress, Psychological

2018
Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case-Control Study Using Automated Health Data Sources.
    CNS drugs, 2019, Volume: 33, Issue:4

    Topics: Acetamides; Adolescent; Antidepressive Agents; Case-Control Studies; Chemical and Drug Induced Liver Injury; Depression; Depressive Disorder, Major; Europe; Female; Humans; Information Storage and Retrieval; Liver; Longitudinal Studies; Male; Retrospective Studies; Selective Serotonin Reuptake Inhibitors

2019
Agomelatine: clinical experience and adherence to EMA recommendations for a novel antidepressant.
    Irish medical journal, 2013, Volume: 106, Issue:2

    Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents; Depression; Female; Guideline Adherence; Humans; Liver Function Tests; Male; Medical Audit; Middle Aged; Practice Guidelines as Topic; Young Adult

2013
Agomelatine, melatonin and depressive disorder.
    Expert opinion on investigational drugs, 2013, Volume: 22, Issue:4

    Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depression; Depressive Disorder; Humans; Melatonin

2013
Agomelatine: a review of adverse effects.
    Prescrire international, 2013, Volume: 22, Issue:136

    Topics: Acetamides; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Depression; European Union; Humans; Receptors, Melatonin

2013
Subgroup analysis of the non-interventional study VIVALDI: agomelatine in treatment-naïve patients, in combination therapy and after treatment switch.
    International journal of psychiatry in clinical practice, 2014, Volume: 18, Issue:2

    Topics: Acetamides; Antidepressive Agents; Circadian Rhythm; Depression; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Treatment Outcome

2014
Does agomelatine have a place in the treatment of depression?
    BMJ (Clinical research ed.), 2014, Mar-20, Volume: 348

    Topics: Acetamides; Antidepressive Agents; Depression; Humans

2014
Treatment with citalopram, but not with agomelatine, adversely affects sperm parameters: a case report and translational review.
    Acta neuropsychiatrica, 2014, Volume: 26, Issue:2

    Topics: Acetamides; Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depression; Humans; Male; Selective Serotonin Reuptake Inhibitors; Semen Analysis; Spermatozoa

2014
[Efficacy and safety of valdoxan in patients with irritable bowel syndrome].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2014, Volume: 114, Issue:4

    Topics: Acetamides; Adult; Antidepressive Agents; Depression; Female; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Psychometrics

2014
Hippocampal and behavioral dysfunctions in a mouse model of environmental stress: normalization by agomelatine.
    Translational psychiatry, 2014, Nov-25, Volume: 4

    Topics: Acetamides; Affective Symptoms; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Epigenesis, Genetic; Hippocampus; Male; Mice; Mice, Inbred C57BL; Neuronal Plasticity; Psychomotor Agitation; Receptors, Melatonin; Serotonin 5-HT2 Receptor Antagonists; Signal Transduction; Stress, Psychological

2014
Odds and ends in psychopharmacology from the past 10 years.
    Journal of psychosocial nursing and mental health services, 2015, Volume: 53, Issue:1

    Topics: Acetamides; Anti-Obesity Agents; Antidepressive Agents; Central Nervous System Stimulants; Depression; Electroencephalography; History, 21st Century; Humans; Mifepristone; Obesity; Psychopharmacology; Stereoisomerism

2015
Agomelatine for Depression in Parkinson Disease: Additional Effect on Sleep and Motor Dysfunction.
    Journal of clinical psychopharmacology, 2015, Volume: 35, Issue:6

    Topics: Acetamides; Aged; Aged, 80 and over; Depression; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Sleep Wake Disorders

2015
Effect of agomelatine on adult hippocampus apoptosis and neurogenesis using the stress model of rats.
    Acta histochemica, 2016, Volume: 118, Issue:3

    Topics: Acetamides; Animals; Antidepressive Agents; Apoptosis; Brain-Derived Neurotrophic Factor; Caspase 3; Depression; Drug Evaluation, Preclinical; Female; Hippocampus; Neurogenesis; Proto-Oncogene Proteins c-bcl-2; Rats, Wistar; Stress, Psychological

2016
[Experience of the antidepressive therapy with valdoxan (agomelatine) in a psychogeriatric unit of the psychiatric hospital].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:11

    Topics: Acetamides; Aged; Antidepressive Agents; Depression; Female; Geriatric Psychiatry; Health Services for the Aged; Hospitals, Psychiatric; Humans; Male; Middle Aged; Treatment Outcome

2015
[Clinical experience of the use of agomelatine in the treatment of patients with depression and chronic brain ischemia].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:12

    Topics: Acetamides; Adult; Anxiety; Brain Ischemia; Chronic Disease; Depression; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Psychiatric Status Rating Scales; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Sleep; Sleep Initiation and Maintenance Disorders

2015
Establishment of an intermittent cold stress model using Tupaia belangeri and evaluation of compound C737 targeting neuron-restrictive silencer factor.
    Experimental animals, 2016, Jul-29, Volume: 65, Issue:3

    Topics: Acetamides; Animals; Antidepressive Agents; Cold-Shock Response; Depression; Epigenesis, Genetic; Female; Humans; Male; Models, Animal; Neurons; Pain; Repressor Proteins; Tupaia; Weight Loss

2016
Augmentation of antidepressant effects of venlafaxine by agomelatine in mice are independent of kynurenine pathway.
    Neurochemistry international, 2016, Volume: 99

    Topics: Acetamides; Animals; Antidepressive Agents; Depression; Drug Synergism; Female; Hindlimb Suspension; Hypnotics and Sedatives; Kynurenine; Male; Mice; Signal Transduction; Swimming; Treatment Outcome; Venlafaxine Hydrochloride

2016
Traxoprodil augments the antidepressant-like activity of agomelatine but not of mianserin or tianeptine in the forced swim test in mice.
    Pharmacological reports : PR, 2016, Volume: 68, Issue:5

    Topics: Acetamides; Animals; Antidepressive Agents; Brain; Depression; Depressive Disorder; Drug Synergism; Male; Mianserin; Mice; Motor Activity; Piperidines; Swimming; Thiazepines

2016
Agomelatine reduces brain, kidney and liver oxidative stress but increases plasma cytokine production in the rats with chronic mild stress-induced depression.
    Metabolic brain disease, 2016, Volume: 31, Issue:6

    Topics: Acetamides; Animals; Brain; Chronic Disease; Cytokines; Depression; Kidney; Liver; Male; Oxidative Stress; Rats; Rats, Wistar; Stress, Psychological

2016
Agomelatine and Transient Elevation of Creatine Phosphokinase.
    Drug research, 2016, Volume: 66, Issue:11

    Topics: Acetamides; Adult; Antidepressive Agents; Creatine Kinase; Depression; Humans; Liver; Liver Function Tests; Male; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2

2016
Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice.
    CNS spectrums, 2017, Volume: 22, Issue:4

    Topics: Acetamides; Adult; Ambulatory Care; Anhedonia; Antidepressive Agents; C-Reactive Protein; Depression; Depressive Disorder, Major; Female; Humans; Hypnotics and Sedatives; Linear Models; Male; Multivariate Analysis; Treatment Outcome; Young Adult

2017
Agomelatine: new drug. Adverse effects and no proven efficacy.
    Prescrire international, 2009, Volume: 18, Issue:104

    Topics: Acetamides; Animals; Antidepressive Agents; Bias; Carcinogens; Clinical Trials as Topic; Cyclohexanols; Depression; Depressive Disorder; Double-Blind Method; Drug Approval; Europe; Fluoxetine; Humans; Hypnotics and Sedatives; Melatonin; Paroxetine; Psychiatric Status Rating Scales; Receptors, Melatonin; Recurrence; Selective Serotonin Reuptake Inhibitors; Suicide; Treatment Outcome; Venlafaxine Hydrochloride

2009
[Clinical experiences with agomelatine. The inner ear has to be synchronized again].
    MMW Fortschritte der Medizin, 2010, Mar-11, Volume: 152, Issue:10

    Topics: Acetamides; Antidepressive Agents; Circadian Rhythm; Controlled Clinical Trials as Topic; Depression; Ear, Inner; Humans; Hypnotics and Sedatives; Melatonin; Nervous System Diseases; Selective Serotonin Reuptake Inhibitors; Sertraline; Sleep Wake Disorders; Tranquilizing Agents

2010
Diazepam discontinuation through agomelatine in schizophrenia with insomnia and depression.
    Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:6

    Topics: Acetamides; Adult; Anti-Anxiety Agents; Depression; Diazepam; Humans; Hypnotics and Sedatives; Male; Schizophrenia; Severity of Illness Index; Sleep Initiation and Maintenance Disorders; Treatment Outcome

2010
[Treatment of patients with moderate and severe nonpsychotic depressions].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010, Volume: 110, Issue:11 Pt 1

    Topics: Acetamides; Adult; Antidepressive Agents; Depression; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Severity of Illness Index; Tranquilizing Agents; Treatment Outcome

2010
Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats.
    Psychopharmacology, 2011, Volume: 217, Issue:3

    Topics: Acetamides; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Cell Proliferation; CREB-Binding Protein; Data Interpretation, Statistical; Depression; Female; Hippocampus; Immunoblotting; Male; Maze Learning; Neurogenesis; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Stress, Psychological

2011
Chronic agomelatine and fluoxetine induce antidepressant-like effects in H/Rouen mice, a genetic mouse model of depression.
    Pharmacology, biochemistry, and behavior, 2011, Volume: 100, Issue:2

    Topics: Acetamides; Animals; Antidepressive Agents; Depression; Disease Models, Animal; Fluoxetine; Locomotion; Mice

2011
Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC.
    Psychopharmacology, 2012, Volume: 221, Issue:3

    Topics: Acetamides; Amygdala; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cognition; Cytoskeleton; Depression; Disease Models, Animal; Hippocampus; Male; Microtubules; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Recognition, Psychology; Synapses

2012
Agomelatine: an antidepressant without deterioration of sexual response.
    Journal of sex & marital therapy, 2012, Volume: 38, Issue:2

    Topics: Acetamides; Adult; Antidepressive Agents; Depression; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Libido; Male; Orgasm; Patient Satisfaction; Sexual Dysfunctions, Psychological; Treatment Outcome; Young Adult

2012
[Clinical experience in using agomelatin (valdoxan) in the neurological practice].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2011, Volume: 111, Issue:11 Pt 1

    Topics: Acetamides; Aged; Benzodiazepines; Depression; Female; Fibromyalgia; Humans; Hypnotics and Sedatives; Male; Middle Aged; Migraine Disorders; Sleep Initiation and Maintenance Disorders; Stroke; Withholding Treatment

2011
[Valdoxan (agomelatine) in combined therapy of moderate and severe non-psychotic depressions].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2012, Volume: 112, Issue:5

    Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents; Depression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Treatment Outcome; Young Adult

2012
Effect of agomelatine in the chronic mild stress model of depression in the rat.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2003, Volume: 28, Issue:4

    Topics: Acetamides; Animals; Antidepressive Agents; Chronic Disease; Chronotherapy; Depression; Disease Models, Animal; Male; Rats; Rats, Wistar; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, Melatonin; Receptors, Serotonin; Stress, Physiological

2003
Antidepressant action of agomelatine (S 20098) in a transgenic mouse model.
    Progress in neuro-psychopharmacology & biological psychiatry, 2005, Volume: 29, Issue:6

    Topics: Acetamides; Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Behavior, Animal; Corticosterone; Depression; Desipramine; Disease Models, Animal; In Situ Hybridization; Male; Maze Learning; Melatonin; Mice; Mice, Transgenic; Receptors, Glucocorticoid; Swimming; Telemetry; Time Factors

2005